TRASTUZUMAB
trastuzumab 60 mg injection, 1 vial
TRASTUZUMAB (4650R)
4650R
Manner of administration:Injection
Restriction (Streamlined authority code: 15820)
Indication: Early HER2 positive breast cancer
Treatment phase: Initial treatment (3 weekly regimen)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1000 mg | # of repeats: 0 | DPMA: $735.71 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Herzuma
(trastuzumab 150 mg injection, 1 vial)
|
||||
| Herzuma
(trastuzumab 440 mg injection [1 vial] (&) inert substance diluent [20 mL vial], 1
pack)
|
||||
| Kanjinti
(trastuzumab 420 mg injection, 1 vial)
|
||||
| Ogivri
(trastuzumab 150 mg injection, 1 vial)
|
||||
| Trazimera
(trastuzumab 60 mg injection, 1 vial)
|
||||
| Trazimera
(trastuzumab 150 mg injection, 1 vial)
|
||||